Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction

被引:2
|
作者
Asakura, Koko [1 ,2 ]
Evans, Scott R. [3 ,4 ]
Hamasaki, Toshimitsu [2 ,3 ,4 ]
机构
[1] Natl Cerebral & Cardiovasc Ctr, Dept Data Sci, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Innovat Clin Trials & Data Sci, Osaka, Japan
[3] George Washington Univ, Biostat Ctr, 6110 Execut Blvd, Rockville, MD 20852 USA
[4] George Washington Univ, Dept Biostat & Bioinformat, 6110 Execut Blvd, Rockville, MD 20852 USA
来源
STATISTICS IN BIOPHARMACEUTICAL RESEARCH | 2020年 / 12卷 / 02期
关键词
Conditional power; Group-sequential designs; Interim analyses; Predicted intervals; Predictive power; Type I error; SAMPLE-SIZE DETERMINATION; TERMINATION; EFFICACY;
D O I
10.1080/19466315.2019.1677494
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We discuss using prediction as a flexible and practical approach for monitoring futility in clinical trials with two co-primary endpoints (CPE). This approach is appealing in that it provides quantitative evaluation of potential effect sizes and associated precision, and can be combined with flexible error-spending strategies. We extend prediction of effect size estimates and the construction of predicted intervals to the two CPE case, and illustrate interim futility monitoring of treatment effects using prediction with an example. We also discuss alternative approaches based on the conditional and predictive powers, compare these methods and provide some guidance on the use of prediction for better decision in clinical trials with CPE.
引用
收藏
页码:164 / 175
页数:12
相关论文
共 48 条
  • [1] Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints
    Asakura, Koko
    Hamasaki, Toshimitsu
    Evans, Scott R.
    BIOMETRICAL JOURNAL, 2017, 59 (04) : 703 - 731
  • [2] Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review
    Hamasaki, Toshimitsu
    Evans, Scott R.
    Asakura, Koko
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (01) : 28 - 51
  • [3] Sample size determination in group-sequential clinical trials with two co-primary endpoints
    Asakura, Koko
    Hamasaki, Toshimitsu
    Sugimoto, Tomoyuki
    Hayashi, Kenichi
    Evans, Scott R.
    Sozu, Takashi
    STATISTICS IN MEDICINE, 2014, 33 (17) : 2897 - 2913
  • [4] Statistical Monitoring of Clinical Trials With Multiple Co-Primary Endpoints Using Multivariate B-value
    Cheng, Yansong
    Ray, Surajit
    Chang, Mark
    Menon, Sandeep
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (03): : 241 - 250
  • [5] Sample size determination in clinical trials with multiple co-primary binary endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    STATISTICS IN MEDICINE, 2010, 29 (21) : 2169 - 2179
  • [6] Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (04) : 650 - 668
  • [7] Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power
    Yang, Jiaying
    Li, Guochun
    Yang, Dongqing
    Wu, Juan
    Wang, Junqin
    Gao, Xingsu
    Liu, Pei
    BMC MEDICAL RESEARCH METHODOLOGY, 2024, 24 (01)
  • [8] Optimal Two-Stage Design for the Phase II Cancer Clinical Trials With Responses and Early Progression as Co-primary Endpoints
    Tan, Xianming
    Takahara, Glen
    Tu, Dongsheng
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (03): : 348 - 354
  • [9] Power analysis for cluster randomized trials with multiple binary co-primary endpoints
    Li, Dateng
    Cao, Jing
    Zhang, Song
    BIOMETRICS, 2020, 76 (04) : 1064 - 1074
  • [10] Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power
    Jiaying Yang
    Guochun Li
    Dongqing Yang
    Juan Wu
    Junqin Wang
    Xingsu Gao
    Pei Liu
    BMC Medical Research Methodology, 24